Mirum falls despite meeting primary goal in phase 3 brelovitug study for hepatitis D

Despite Mirium Pharmaceuticals achieving major Phase 3 targets for Brelomivir, a treatment for hepatitis B delta virus, the stock price fell.

AI CATALYST SCORE45 / 100Score computed by Sentinel V12

REFERENCE PRICENot measuredReference entry price at analysis time

ANALYSIS HISTORY

MIRM Analysis History (Last 30 Days)

Diagnosed At	Ticker	AI Score	Tier
2026-10-12 14:27:30	MIRM	85	Mid	View Report →
2026-10-11 21:23:14	MIRM	35	Row	View Report →
2026-09-28 15:47:00	MIRM	45	Mid	View Report →

RELATED REPORTS

Diagnosed At	Ticker	AI Score	Tier
2026-10-12 20:42:18	SNDX	50	Mid	View Report →
2026-10-12 20:15:11	NRIX	88	Mid	View Report →
2026-10-12 18:38:43	NKTR	65	Mid	View Report →
2026-10-12 17:03:53	AZN	45	Mid	View Report →
2026-10-12 15:13:48	BMY	45	Mid	View Report →
2026-10-12 11:54:45	SNDX	60	Mid	View Report →
2026-10-12 11:20:22	BMY	84	Mid	View Report →
2026-10-12 09:05:56	BIIB	78	S-Class	View Report →
2026-10-11 16:45:25	MRK	55	Mid	View Report →
2026-10-11 16:11:22	BBIO	82	Mid	View Report →
2026-10-11 13:11:02	ZYME	35	Row	View Report →
2026-10-11 11:10:29	INSM	42	Row	View Report →
2026-10-11 08:45:43	ETON	30	Row	View Report →
2026-10-11 01:58:05	TWST	35	Row	View Report →
2026-10-11 00:12:02	UTHR	35	Row	View Report →
2026-10-10 22:48:32	MRK	65	Mid	View Report →
2026-10-10 19:28:19	ZYME	20	Row	View Report →
2026-10-10 08:26:54	ANAB	85	Mid	View Report →
2026-10-09 21:09:20	HIMS	55	Mid	View Report →
2026-10-09 21:03:55	MRNA	78	S-Class	View Report →
2026-10-09 20:17:07	PCVX	45	Mid	View Report →
2026-10-09 17:43:30	VRTX	78	Mid	View Report →
2026-10-09 15:11:18	LLY	60	Mid	View Report →
2026-10-09 04:08:40	UTHR	40	Row	View Report →
2026-10-08 17:38:59	NGNE	72	Mid	View Report →
2026-10-08 16:47:23	RCKT	65	Mid	View Report →
2026-10-08 16:05:20	EDIT	82	S-Class	View Report →
2026-10-08 15:28:31	ADCT	45	Mid	View Report →
2026-10-08 12:30:11	BMY	82	Mid	View Report →
2026-10-08 11:52:13	MRK	40	Row	View Report →